Health economics perspective of fesoterodine, tolterodine or solifenacin as first-time therapy for overactive bladder syndrome in the primary care setting in Spain

Peer Review reports

Original Submission
25 Jun 2013	Submitted	Original manuscript
1 Sep 2013	Reviewed	Reviewer Report - Jian Gong
4 Sep 2013	Reviewed	Reviewer Report - Oriol de Solà-Morales
23 Sep 2013	Author responded	Author comments - Javier Rejas
Resubmission - Version 2
23 Sep 2013	Submitted	Manuscript version 2
Publishing
11 Oct 2013	Editorially accepted
21 Oct 2013	Article published	10.1186/1471-2490-13-51

Back to article page